What if you could detect cancer just as it is getting started? New research published in the journal Nature just might give medicine the tools to do just that.

South San Francisco-based Veracyte entered a multi-year partnership with AstraZeneca’s hematology research and development unit, Acerta Pharma.

Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.